This spanned 2195 glioblastoma, 1198 IDH1/2-mutant astrocytoma, 531 IDH1/2-mutant oligodendroglioma, 271 other IDH1/2-wild-type glioma, and 205 pediatric-type glioma (89 low-grade, 116 high-grade), all classified according to the World Health Organization (WHO) Classification of Tumors of the Central Nervous System 2021 guidelines and the 6 cIMPACT-NOW Updates.5,6. This evidence concerns the gene IDH1 and glioma.